UBS Initiates Coverage On Immunocore Hldgs with Sell Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on Immunocore Holdings (NASDAQ:IMCR) with a Sell rating and set a price target of $24.
October 24, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst David Dai has initiated coverage on Immunocore Holdings with a Sell rating and a price target of $24, suggesting potential downside.
The initiation of coverage with a Sell rating by UBS and a price target of $24 suggests that the analyst expects the stock to underperform. This could lead to a negative short-term impact on the stock price as investors may react to the bearish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100